Caristo Diagnostics, an Oxford, UK-based biotechnology company which specializes in cardiac and vascular disease diagnostics and risk prediction, raised US$16.3M in Series A funding.
The round was led by Oxford Science Enterprises and joined by BGF, Longwall Venture Partners, Oxford Investment Consultants LLP, Oxford University and other investors.
The company intends to use the funds to advance its CaRi-Heart technology, an AI-assisted diagnostics and risk prediction tool, into standards of cardiac care in global markets.
Founded in 2018 and led by CEO Frank Cheng, Caristo Diagnostics is a company focused on heart and vascular disease diagnostics and risk prediction. A spin-out of the University of Oxford, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid in the prediction and diagnosis of heart attack, stroke and diabetes. Its CaRi-Heart provides an AI algorithms thst allows trained health professionals to obtain measures of coronary inflammation from routine cardiac computed tomography angiography (CCTA) scans by using its Fat Attenuation Index (FAI) technology. The resulting FAI Score measures the risk of cardiac mortality due to coronary inflammation. Additionally, CaRi-Heart offers a long-term cardiac mortality risk by integrating coronary inflammation with standard clinic risk factors and the presence of coronary plaques.
FinSMEs
17/04/2023